1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DDBB6482E4D56D79002585C4001A3DDE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-medical-affairs-hematology-product-launches-role-activities?opendocument
18
19opendocument
2018.97.14.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Maximizing the Impact of Medical Affairs in Hematology Product Launches: Role and Activities

ID: 5627


Features:

16 Info Graphics

13 Data Graphics

260+ Metrics

10 Narratives


Pages/Slides: 39


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Medical Affairs in Hematology Product Launches: Role and Activities”

STUDY OVERVIEW

Biopharma companies seeking to differentiate their hematological therapies at launch are increasingly turning to their own medical experts. As a critical conduit between biopharma and external healthcare decision makers, the Medical Affairs function drives many of the critical activities spanning pre-launch, launch and post-launch.

And to maximize the impact of Medical Affairs in hematology launches, it is vital to clarify the emerging roles and activities that the medical function is responsible for.

Best Practices, LLC conducted this benchmarking research to explore how Medical Affairs can maximize its hematology launch impact. This study provides insights and benchmarks around strategy planning, role, activities, cross-functional alignment and collaboration for an effective hematology launch.

KEY TOPICS
  • Medical Affairs role and activity effectiveness
  • Ensuring cross-functional alignment and collaboration
  • Adapting to ongoing changes in Medical Affairs landscape
  • Medical Affairs leading vs. supporting brand teams

KEY METRICS
  • What role does your Medical Affairs group play at launch in listed areas?
  • How effective is your Medical Affairs organization in regards to listed activities for a successful launch?
  • How does your Medical Affairs work with internal colleagues to ensure successful launch?
  • What is the role of your Medical Affairs group in cross-functional hematology launch teams?
  • What are the major pitfalls for Medical Affairs during hematology launch?

SAMPLE KEY FINDINGS
  • Medical Affairs can significantly boost its launch performance by improving brand team collaboration and alignment:
    • Improve brand team collaboration through team leadership structures, clear roles and responsibilities and by enabling activity ownership structures.
    • Improve brand team alignment by deploying work timelines and increasing strategy transparency to 24 months before the launch.
METHODOLOGY

Best Practices, LLC engaged over 19 hematology Medical Affairs experts from 14 pharmaceutical and biotechnology companies in this research study through a benchmarking survey, interviews and a roundtable discussion.


Industries Profiled:
Pharmaceutical; Biotech; Chemical; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Celgene; Crescendo Bioscience; Curis; Daiichi Sankyo; Grifols; Orchard Therapeutics; Roche; Sandoz; Sanofi; Servier; Shire; Takeda Pharmaceuticals; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.